Basic Information | Post buying leads | Suppliers |
Name |
Colistimethate sodium |
EINECS | 232-516-9 |
CAS No. | 8068-28-8 | Density | N/A |
PSA | 0.00000 | LogP | 0.00000 |
Solubility | Freely soluble in water | Melting Point |
N/A |
Formula | C58H105N16Na5O28S5 | Boiling Point | N/A |
Molecular Weight | 1749.82 | Flash Point | N/A |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes | N/A | |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
Colistinmethanesulfonicacid (6CI);Colimycin M;Colimycin sodium methanesulfonate;Colistimethate;Colistinsodium methanesulfonate;Colistin sulfomethate;Colistin sulfomethate sodium;Colistin, methyl sulfate, sodium salt;Colistinat;Coly-Mycin injectable;Colymycin M;Sodium colistimethate;Sodium colistinmethanesulfonate;W 1929; |
The Colistimethate sodium, with the CAS registry number 8068-28-8, is also known as Colistinemethanesulfonate sodique. Its EINECS number is 232-516-9. This chemical's molecular formula is C58H105N16Na5O28S5 and molecular weight is 1749.82. What's more, its systematic name is Pentasodium [(4-{[3-(1-hydroxyethyl)-12,15-diisobutyl-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris{2-[(sulfonatomethyl)amino]ethyl}-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]amino}-3-{[3-hydroxy-2-({2-[ (6-methyloctanoyl)amino]-4-[(sulfonatomethyl)amino]butanoyl}amino)butanoyl]amino}-4-oxobutyl)amino]methanesulfonate. Its classification codes are: (1)Antibacterial; (2)Drug / Therapeutic Agent; (3)Human Data; (4)Reproductive Effect.
You can still convert the following datas into molecular structure:
(1)SMILES: [Na+].[Na+].[Na+].[Na+].[Na+].O=S([O-])(=O)CNCCC(NC(=O)CCCCC(C)CC)C(=O)NC(C(=O)NC(C(=O)NC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC1)C(O)C)CCNCS([O-])(=O)=O)CCNCS([O-])(=O)=O)CC(C)C)CC(C)C)CCNCS([O-])(=O)=O)CCNCS([O-])(=O)=O)C(O)C
(2)Std. InChI: InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5
(3)Std. InChIKey: IQWHCHZFYPIVRV-UHFFFAOYSA-I
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | LDLo | intramuscular | 90mg/kg/18H-I (90mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED | JAMA, Journal of the American Medical Association. Vol. 207, Pg. 2099, 1969. |
guinea pig | LD50 | intramuscular | 444mg/kg (444mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 21, Pg. 737, 1981. | |
human | TDLo | intramuscular | 56700ug/kg/9D (56.7mg/kg) | KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | Annals of Internal Medicine. Vol. 66, Pg. 1052, 1967. |
mouse | LD50 | intramuscular | 748mg/kg (748mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 21, Pg. 737, 1981. | |
mouse | LD50 | intraperitoneal | 126mg(base)/k (126mg/kg) | Antibiotics Annual. Vol. 7, Pg. 41, 1959/1960. | |
mouse | LD50 | intravenous | 222mg(base)/k (222mg/kg) | Antibiotics Annual. Vol. 7, Pg. 41, 1959/1960. | |
mouse | LD50 | oral | > 767mg(base)/ (767mg/kg) | Antibiotics Annual. Vol. 7, Pg. 41, 1959/1960. | |
mouse | LD50 | subcutaneous | 138mg(base)/k (138mg/kg) | Antibiotics Annual. Vol. 7, Pg. 41, 1959/1960. | |
rabbit | LD50 | intramuscular | 465mg/kg (465mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 21, Pg. 737, 1981. | |
rat | LD50 | intramuscular | 44mg/kg (44mg/kg) | Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971. | |
rat | LD50 | intraperitoneal | 86mg/kg (86mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) | Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 541, 1973. |
rat | LD50 | oral | 5450mg/kg (5450mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) | Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 541, 1973. |
rat | LD50 | subcutaneous | 87mg/kg (87mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) | Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 541, 1973. |